Free Trial
NASDAQ:GNTA

Genenta Science (GNTA) Stock Price, News & Analysis

Genenta Science logo
$4.70 0.00 (0.00%)
(As of 12:30 PM ET)

About Genenta Science Stock (NASDAQ:GNTA)

Key Stats

Today's Range
$4.60
$5.00
50-Day Range
$3.30
$6.92
52-Week Range
$2.20
$7.28
Volume
4,194 shs
Average Volume
10,144 shs
Market Capitalization
$85.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.00
Consensus Rating
Buy

Company Overview

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.

Genenta Science Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
48th Percentile Overall Score

GNTA MarketRank™: 

Genenta Science scored higher than 48% of companies evaluated by MarketBeat, and ranked 615th out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Genenta Science has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Genenta Science has only been the subject of 1 research reports in the past 90 days.

  • Read more about Genenta Science's stock forecast and price target.
  • Earnings Growth

    Earnings for Genenta Science are expected to decrease in the coming year, from ($0.93) to ($1.09) per share.

  • Price to Book Value per Share Ratio

    Genenta Science has a P/B Ratio of 3.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.03% of the outstanding shares of Genenta Science have been sold short.
  • Short Interest Ratio / Days to Cover

    Genenta Science has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Genenta Science has recently decreased by 54.31%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Genenta Science does not currently pay a dividend.

  • Dividend Growth

    Genenta Science does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.03% of the outstanding shares of Genenta Science have been sold short.
  • Short Interest Ratio / Days to Cover

    Genenta Science has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Genenta Science has recently decreased by 54.31%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Genenta Science this week, compared to 0 articles on an average week.
  • Search Interest

    1 people have searched for GNTA on MarketBeat in the last 30 days.
  • MarketBeat Follows

    Only 1 people have added Genenta Science to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Genenta Science insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    28.99% of the stock of Genenta Science is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 15.13% of the stock of Genenta Science is held by institutions.

  • Read more about Genenta Science's insider trading history.
Receive GNTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genenta Science and its competitors with MarketBeat's FREE daily newsletter.

GNTA Stock News Headlines

Genenta Science (NASDAQ:GNTA) Trading Down 4.9% - Time to Sell?
Man behind OpenAI makes shocking new bet
Billionaire Sam Altman has become one of the most powerful men in the world by running OpenAI… But there’s a far lesser known investment he’s making that could put OpenAI to shame. In fact this Sam Altman-backed company could actually become a crucial partner for OpenAI… And the US Military… not to mention hundreds of other giant companies around the globe. To make the story even crazier… this company only recently became viable, thanks to an obscure piece of legislation that President Trump signed before he left office… Which ordered the government to take this incredible new technology seriously.
See More Headlines

GNTA Stock Analysis - Frequently Asked Questions

Genenta Science's stock was trading at $4.95 at the beginning of 2024. Since then, GNTA shares have decreased by 7.1% and is now trading at $4.60.
View the best growth stocks for 2024 here
.

Genenta Science (GNTA) raised $28 million in an initial public offering on Wednesday, December 15th 2021. The company issued 2,400,000 shares at $10.50-$12.50 per share.

Shares of GNTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Genenta Science investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), PDD (PDD) and AppLovin (APP).

Company Calendar

Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GNTA
Fax
N/A
Employees
7
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$25.00
High Stock Price Target
$25.00
Low Stock Price Target
$25.00
Potential Upside/Downside
+431.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.21 per share

Miscellaneous

Free Float
12,988,000
Market Cap
$85.96 million
Optionable
Not Optionable
Beta
0.74
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for December 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

This page (NASDAQ:GNTA) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners